Purified forms of DNase
AssigneeGenentech, Inc.
InventorsJohn Frenz, Steven J. Shire, Mary B. Sliwkowski
Life of this patent
Estimating the term…
Abstract
The present invention provides the identification and characterization of two components of a recombinant preparation of DNase. These components are the purified deamidated and non-deamidated human DNases. Taught herein are the separation of these components and the use of the non-deamidated species as a pharmaceutical per se, and in particular in compositions wherein the species is disclosed within a plastic vial, for use in administering to patients suffering from pulmonary distress.
Claims4
A pharmaceutical composition comprising non-deamidated human DNase disposed in contact with a container fabricated of other than glass wherein less than about 5% by weight of the total DNase is deamidated at the amino acid corresponding to Asn 74.
A pharmaceutical composition comprising non-deamidated human DNase in a plastic vial wherein less than about 5% by weight of the total DNase is deamidated at the amino acid corresponding to Asn 74.
A pharmaceutical composition comprising non-deamidated human DNase in a plastic vial wherein less than about 1% by weight of the total DNase is deamidated at the amino acid corresponding to Asn 74.
A pharmaceutical composition consisting of non-deamidated human DNase as the active principle and optionally a pharmaceutically acceptable excipient disposed in contact with a container fabricated of other than glass.
Dependencies are inferred from the claim text.